PYMX MNTA: As noted in reply to your post on SI (http://siliconinvestor.advfn.com/readmsg.aspx?msgid=26587522 ), the cumbersome process that’s apparently required for PMX-60056 to reverse Lovenox is a boost, albeit a small one, for MNTA’s M118, which can be fully reversed with protamine (#msg-39146357). I consider this a small boost for M118 rather than a big boost because the target market for M118 is ACS and Lovenox is not a big factor in that market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.